Kymera Therapeutic/$KYMR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kymera Therapeutic
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
- Ticker
- $KYMR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 273
- Headquarters
- Watertown, United States
- Website
- www.kymeratx.com
KYMR Metrics
BasicAdvanced
$9.4B
-
-$3.21
1.95
-
Price and volume
Market cap
$9.4B
Beta
1.95
52-week high
$130.05
52-week low
$55.26
Average daily volume
839K
Financial strength
Current ratio
10.337
Quick ratio
9.968
Long term debt to equity
0.043
Total debt to equity
0.052
Interest coverage (TTM)
-1,024.63%
Profitability
EBITDA (TTM)
-339.891
Gross margin (TTM)
-257.68%
Net profit margin (TTM)
-285.33%
Operating margin (TTM)
-329.83%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-15.59%
Return on equity (TTM)
-24.15%
Valuation
Price to revenue (TTM)
100.048
Price to book
6.18
Price to tangible book (TTM)
6.18
Price to free cash flow (TTM)
-44.147
Free cash flow yield (TTM)
-2.27%
Free cash flow per share (TTM)
-2.551
Growth
Revenue change (TTM)
134.84%
Earnings per share change (TTM)
-7.59%
3-year revenue growth (CAGR)
26.66%
3-year earnings per share growth (CAGR)
5.25%
What the Analysts think about KYMR
Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.
Analyst projections of the future price of Kymera Therapeutic stock.
Bulls say / Bears say
KT-621 has shown early signs of patient benefit: Kymera’s Phase 1b report describes improvements in itch and sleep in people with moderate-to-severe atopic dermatitis. This adds clinical promise to the drug’s biological target-engagement results, though larger trials still need to confirm it. (Kymera Therapeutics)
Kymera completed enrolment in its atopic dermatitis Phase 2b trial nearly six months ahead of schedule, bringing the expected results forward to year-end 2026. If the data support it and regulators agree, Phase 3 trials could start by mid-2027. (SEC)
Kymera reported $1.5 billion in cash, cash equivalents and investments at the end of June 2026 and expects its runway to extend into 2029. That should fund several clinical milestones without the immediate need for new capital. (Kymera Therapeutics)
The patient-benefit evidence remains preliminary: Kymera said its longest Phase 1b study lasted 28 days, while the Phase 2b trial is testing outcomes over 16 weeks. Elevated placebo responses in atopic dermatitis trials could also make it harder to show a clear treatment effect. (Investing.com, The Motley Fool)
Kymera has no approved products and remains loss-making; second-quarter R&D spending rose to $119.5 million from $78.4 million a year earlier. The quarter’s $65 million in collaboration revenue came from partner payments, which may not recur at the same pace. (SEC)
Kymera’s potential first-in-class status may not guarantee lasting differentiation: Pfizer, Nurix and Sanofi are also developing STAT6-related programmes. More competition could make it harder to stand out and win market share if KT-621 reaches the market. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
KYMR Financial Performance
Revenues and expenses
KYMR Earnings Performance
Company profitability
Upcoming events
No upcoming events
KYMR News
AllArticlesVideos
Funds containing KYMR
AllUSDEURGBP
Fund name | Fund size | $KYMR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.62% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.62% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.24% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.24% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.